Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
When a deal is announced it has to be approved by the shareholders, which might take a few weeks, and then they'd be a couple of weeks before the money is paid.
However, if a deal of say £1 per share is announced, the share price would immediately be around 97p due to normal trading.
If you think there's going to be a 'third wave' in the UK, then clearly you don't think vaccines work, and must be an anti-vaxx conspiracy theorist.
Even more for Mr John Story.
I've attempted to phone a couple of times this morning to move some different shares and have given up after waiting 20/30 minutes for them to answer (sadly my employer seems to think I should be doing some work). Obviously it's busy at the moment though, other times it's been fine.
The 'engagement with banks' RNS was 18 months ago. This is taking a looooong time. I'm fully aware of the complexity of everything and covid etc, but I think something was holding us up, and I'm hoping it was revealed last Friday.
...has gone mental...
RNS Number : 9702T
Tiziana Life Sciences PLC
30 March 2021
Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
New York/London, 30 March 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug Administration (FDA) has allowed evaluation of nasal administration with Foralumab, a fully human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women's Hospital (BWH), Harvard University, Boston, MA. This patient will be treated under an Individual Patient Expanded Access IND. This is the first time a nasally administered antibody will be administered to a patient with SPMS. The treatment is planned to start in the second quarter of 2021, and will continue for six months. Investigators at BWH will follow this patient with detailed routine safety, neurological, imaging and PET studies to evaluate microglial imaging. Modification of immunological and neurodegenerative markers is part of standard investigations that will be conducted at the BWH.
Previously, Tiziana completed a Phase 1 trial of a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) once a day dosing for 5 consecutive days with nasally administered Foralumab in healthy subjects. The treatment was well-tolerated with no drug-related safety issues reported at any doses up to 250 mg of the doses. Nasal foralumab was developed by Professor Howard Weiner at BWH.
Weiner commented, "Nasal anti-CD3 is an exciting, novel approach that has the ability to provide a safe treatment for a form of MS that has no effective treatment. We are pleased that the FDA has allowed us to treat a patient with SPMS who needs a better treatment option than is currently available."
Dr. Tanuja Chitnis, Professor of Neurology at Harvard Medical School and senior neurologist at the BWH, adds, "New treatments for progressive MS are urgently needed. Nasal Foralumab could revolutionize treatment for this disabling form of disease."
The company had previously reported positive data from the Clinical Study of Nasal Administration with Foralumab in COVID-19 patients in Brazil. Nasally administered Foralumab at 100 mg/day for consecutive 10 days treatment was found to be well-tolerated, and there were no apparent severe adverse events. The clinical data suggested that the treatment provided significant reduction of lung inflammation.
About Foralumab
Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases in the classic s
Well, obviously they read the board...they've released an RNS...
As it's a bit quiet, I bought some of the 'Tropical' gummies last summer and they were Lemon/Lime and Mango flavour. Just bought some more and they're Pineapple and Passion Fruit flavour. Did I miss something?
"The next step for Napster is to launch a subscription service with a monthly fee."
????